^
Association details:
| Biomarker: | NRAS wild-type |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Vectibix (panitumumab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MONARCC: A randomised phase II study of Panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer.
Excerpt:
...RAS (KRAS exons 2,3 and 4; NRAS exons 2 and 3) wild type as assessed by the investigator's choice of testing laboratory....
Trial ID:
Source:
Title:
A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer
Excerpt:
...Participants classified as KRAS/NRAS wild-type** by KRAS/NRAS testing*....
Trial ID:
More C2 evidence
Source:
Title:
Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer
Excerpt:
...Patients with wild-type RAS (KRAS and NRAS) status of metastatic colorectal cancer treatment with panitumumab according to label...
Trial ID:
Source:
Title:
FOLFOXIRI plus Panitumumab or FOLFOX plus Panitumumab in the treatment of metastatic colorectal cancer. folfoxiri più panitumumab contro folfox più panitumumab nel carcinoma del colonretto metastatico.
Excerpt:
...Histologically proven diagnosis of colorectal cancer.Initially unresectable metastatic colorectal cancer not previously treated with chemotherapy for metastatic disease.At least one measurable lesion according to RECIST1.1Availability of a tissue tumour sample (primary tumour and/or metastatic sites)Previous adjuvant chemotherapy allowed only if with fluoropyrimidine monotherapy and more than 6 months elapsed between the end of adjuvant and first relapse.RAS (codons 12, 13, 59, 61, 117 and 146 of KRAS and NRAS genes) and BRAF (V600E mutation) wild type status of primary colorectal cancer or related metastasis (local or central laboratory assessment). ...
Trial ID:
Source:
Title:
Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC
Excerpt:
...Patients classified as KRAS/NRAS wild-type by KRAS/NRAS testing....
Trial ID:
Source:
Title:
Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer
Excerpt:
...- Wild-type KRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) and wild-type NRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) tumor status....
Trial ID:
Source:
Title:
Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma
Excerpt:
...However, the criteria will be changed to all patients who are verified to be of KRAS and NRAS wild-type when the KRAS and NRAS tests come to be covered by National Health Insurance, and the tests become feasible at medical institutions....
Trial ID:
Less C2 evidence
Source:
Title:
Right vs left-sided RAS wild-type metastatic colorectal cancer treated with EGFR inhibitors: prognostic differences
Excerpt:
CONTRADICTING EVIDENCE: A retrospective study of a total of 44 patients with metastatic and KRAS/NRAS wt status CRC, treated with cetuximab or panitumumab was performed...In patients with mCRC RAS wt treated with EGFR inhibitors, regardless of the line of treatment, the right-side location was associated with poor survival...
DOI:
https://doi.org/10.1093/annonc/mdz155.193
Source:
Title:
Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer
Excerpt:
Approximately half of all patients with metastatic colorectal cancer (mCRC) have KRAS and NRAS (RAS) wild-type tumor…The combination of cabozantinib and panitumumab had signals of clinical activity. A lower starting dose of cabozantinib may offer comparable clinical activity and improved long-term tolerability.
DOI:
https://doi.org/10.1002/onco.13678
Trial ID:
Source:
Title:
FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
Excerpt:
The median overall survival (OS) was 26 months in the patients with wild-type KRAS and wild-type NRAS mCRC. It was 90.4% for the 6-month OS, 79.5% for the 1-year OS, 53.7% for the 2-year OS and 31.1% for the 3-year OS….The first-line FOLFIRI plus panitumumab was associated with favourable efficacy in the patients with wild-type KRAS and wild-type NRAS mCRC, and it was well tolerated.
DOI:
10.1186/s12957-018-1359-9
